MAIA Biotechnology (MAIA)

• Market cap: $50M
• 1 day: -0.74%
• 5 days: 6.3%
• 1 month: 35%
• 3 months: -21.05%
• 6 months: -21.51%
• Year to date: -35.41%
• 1 year: -38.64%
• 5 years: -69.73%
• 10 years: -69.73%
• Sector: Healthcare
• Industry: Drug Manufacturers - General

About: MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.

Employees: 13